Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 7/30

$10.26+0.09 (+0.88%)

Close on Nov 11, 2026Market cap $170.12MP/E –Yield –

Sutro Biopharma gross margin

Gross margin is gross profit as a percentage of revenue.

Sutro Biopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Sutro Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 3, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing